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ABSTRACT: Recommender systems (RSs), which underwent rapid development and had an enormous impact on e-commerce,
have the potential to become useful tools for drug discovery. In this paper, we applied RS methods for the prediction of the antiviral
activity class (active/inactive) for compounds extracted from ChEMBL. Two main RS approaches were applied: collaborative
filtering (Surprise implementation) and content-based filtering (sparse-group inductive matrix completion (SGIMC) method). The
effectiveness of RS approaches was investigated for prediction of antiviral activity classes (“interactions”) for compounds and viruses,
for which some of their interactions with other viruses or compounds are known, and for prediction of interaction profiles for new
compounds. Both approaches achieved relatively good prediction quality for binary classification of individual interactions and
compound profiles, as quantified by cross-validation and external validation receiver operating characteristic (ROC) score >0.9.
Thus, even simple recommender systems may serve as an effective tool in antiviral drug discovery.
1. INTRODUCTION
Multitask learning1 gained popularity in different fields by virtue
of continued rapid growth of available information and the
development of advanced algorithms. The advantage of
multitask learning is that it provides an opportunity to use
additional information from related tasks for prediction for a
task with insufficient information. It allows one both to improve
the prediction performance and to process small or imbalanced
data sets that are prevalent in the drug discovery field.2
The multitask learning approaches in different fields evolved
separately and are characterized by different definitions and
notations (see the Appendix 1). The concept of multitask
learning has become popular in chemoinformatics3−7 and the
clearest examples of its realization were the proteochemomet-
rics8−10 and “read across” approach.11 In e-commerce, multitask
learning is referred to as the recommender system (RS).
RS is one of the approaches12 based on multitask learning and
allows one to realize multitask prediction (occasionally referred
to as multitarget prediction13). The interest in RS began to
increase in October 2006 with the announcement of a Netflix
Prize competition,14,15 aiming to create a precise system to
analyze users’ preferences and suggest video content for them.
RS methods are classified, based on the information used for
model creation, into collaborative filtering (CF), content-based
filtering (CBF), hybrid approaches, and others.16,17 The choice
of approach for a certain task is grounded on the required
prediction accuracy and available computational resources.18−20
Collaborative filtering (CF)16,21,22 is one of themost common
RS methods, popularized during the Netflix competition due to
its simplicity. If users have similar preferences, then they have
similar profiles and vice versa. A CF RS model recommends new
content to a user based on its evaluation of other users with
similar preference profiles. In the drug discovery context, CF
methods may rely on the similarity between compound or target
interaction profiles to predict interaction values and select
compound−target pairs with higher interaction scores.
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CF methods are the easiest to implement but have a lot of
limitations.16,23−25 The most important one is the cold-start
problem (CS): interaction values cannot be reliably predicted
for pairs consisting of new compounds or targets due to an
inability to calculate similarity for their (empty) interaction
profiles. The second limitation is the sparsity problem: the fewer
the interaction values known, the more complicated it is to
calculate similarity. The third limitation is scalability: the
computational and memory complexities of CF algorithms are
generally quadratic.
Content-based filtering (CBF) RS methods are more
advanced and allow one to predict interaction values based on
additional feature information, also called side-channel
information, which characterizes both compounds and
targets.16,26,27 CBF recommends items similar to those liked
by a user in the past based on the assessment of similarity of their
features. In drug discovery, CBFmay employ similarity based on
features, or descriptors, of compounds or targets. Feature
information allows one to overcome the disadvantages inherent
to CF methods: prediction for new compounds or targets and
very sparse data matrices. Also, a valuable advantage of CBF
algorithms is the possibility of interpreting the model by analysis
of important features. The disadvantages of CBF include the
ability of overfitting and the need for feature calculation, which
may be complicated in the case of target characterization.
Among the rapidly growing number of multitask prediction
applications in drug discovery, only a couple of dozen studies
regarded their approaches as RS. These studies were usually
concerned with the analysis of approved drugs and their possible
side effects,28−30 drug repurposing,30−33 drug−drug interac-
tions,34,35 toxicogenomics prediction,36 or treatment recom-
mendations.37,38 A comparison of several methods demon-
strated the possibility to successfully use rather simple RS
algorithms in drug discovery.39 Also, there were publications
describing newmethods of matrix completion with validation on
drug databases,40 and estimating their robustness on bioactivity
data sets.41 In clinical medicine, RSs have been applied since
2008 to improve treatment recommendation schemes. For
example, the RS approaches were used for automatic detection
of omissions in medication lists,42,43 as well as for treatment
optimization in the context of the information overload
problem, by suggesting knowledge-based items of interest to
clinicians for specific diseases.44
The search for new antivirals is an attractive field for the
application of the RS approach. It is rather different from other
medicinal chemistry fields because the majority of primary
antiviral activity data are obtained from phenotypic antiviral
assays, usually cell-based.45 Contrary to common approaches,
where targets are represented by individual proteins, antiviral
activity is usually measured in much more complicated systems,
containing at least viruses, cells, and compounds, and
approaches based on individual targets are of limited use here.
Thus, the search for broad-spectrum antivirals or antivirals
against less-studied viruses reduces to the application of
common molecules or privileged classes, such as nucleosides,
as could be seen during the current coronavirus disease
pandemic.46−48 In our previous studies, we compiled a large
annotated data set of small-molecule antiviral activity,
ViralChEMBL v. 0.1.45 After filtering, the data on activity and
inactivity of approximately 250K compounds against 158 viral
species were represented as a sparse matrix of compound−virus
interactions, containing only 400K data points of 40M possible.
Typically, the sparsity of interaction matrixM in the RS setting
reaches 90−99%,49,50 so this data set forms a proper base for the
development of predictive models based on matrix completion
methods.
In this paper, we present an attempt to apply RS approaches in
the antiviral drug discovery context. To complete the antiviral
activity matrix, we used the CF algorithm implemented in
Surprise package51 and sparse-group inductive matrix com-
pletion (SGIMC) implementation of CBF.52 Several questions
were addressed in our study: (1) Are the RS approaches effective
in the context of antiviral activity prediction taking into account
the data sparsity and unusual complexity of targets (viruses)? (2)
Which RS approach gives a more accurate prediction? (3) Can
we obtain a reliable prediction result for new compounds or new
viral species? To address these challenges, we developed
scenarios for prediction of new point interactions for
compounds and viruses, which were used for model building,
and prediction of interaction profiles for new compounds or
viruses, not used for model building.
2. MATERIALS AND METHODS
2.1. Recommender System Approaches. 2.1.1. Collabo-
rative Filtering. We used CF implementation of the Surprise
Python package.51 The methods we used operate only the
interaction matrix elements and can be divided into three
groups:
• k-Nearest-neighbor (kNN)-based algorithms are imple-
mented in knns.KNNBasic class and identify the neighbors
for the compounds and viruses based on the similarity of
their interaction profiles. We used cosine similarity and
mean-squared differencemetrics for similarity calculation.
• Clustering algorithms are implemented in the co_cluster-
ing.CoClustering class. They identify the neighborhood by
grouping compounds or viruses into coclusters, simulta-
neously clustering the columns and rows of a matrix, and
generate predictions based on the average interaction
values.
• Matrix factorization algorithms are represented by
singular value decomposition (matrix_factorization.SVD)
and non-negative matrix factorization (matrix_factoriza-
tion.NMF) methods. They are based on the idea of
interaction matrix decomposition and determination of
the latent variables allowing for completion of the missing
interaction values.
Model hyperparameters are given in Supporting Information
Table S1.
2.1.2. Content-Based Filtering. The sparse-group inductive
matrix completion algorithm implemented in the SGIMC
package52 was used as an example of CBF RS. It is based on
the inductive matrix completion (IMC) method and allows one
to filter out noninformative features. To recover the missing
entries of matrix M n n1 2∈ × , where only Mij for (i, j) ∈ Ω ⊂
{1,...,n1} × {1,...,n2} are known, IMC takes into account side
feature information provided in matrices X and Y. In our case,
X n d1 1∈ × contains descriptors of the compounds and
Y n d2 2∈ × contains virus features (here, taxa), n1 and n2 are
the numbers of compounds and species, and d1 and d2 are the
numbers of their features, respectively.
The approach is based on the assumption that the elements of
the matrixMmay be predicted via a bilinear model:Mij∼ xiTWyj
for a low-rank matrix W d d1 2∈ × , given that the features are
predictive. As the matrix W must have rank k < min (d1; d2),
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according to the constraint of the inductive matrix completion
approach, the matrix W can be represented by a low-rank
product UVT with U d k1∈ × and V d k2∈ × . Then, the
penalized minimization problem is solved
3 M R RXUV Y U Vmin ( , ( ) ) ( ) ( )
U V i j
ij ij U V
,
( , )
T T∑ λ λ+ +
∈Ω
(1)
where 3:   × → is the smooth convex loss function for
the binary classification problem, log(1 + e−yp) for y and p as
known and predicted values, respectively. R(·) is the penalty,
and λV and λU are the appropriate regularization coefficients.
The SGIMC algorithm shares the idea of the IMC approach
of matrix completion by combining feature vectors associated
with rows and columns of an interaction matrix with a low-rank
matrix. The method differs by application of the sparse-group
penalty for selection of side features, in addition to the classic
ridge and lasso regularizations used in IMC. Thus, the penalty
function R(·) is represented as a sum of three terms: sparsity-
inducing penalty ∥Z∥2,1, the squared Frobenius norm ∥Z∥F2, and
the matrix L1-norm ∥Z∥1,1
R C C C
C z C z C e
Z Z Z Z
Z
( )Z
i
n
j
d
ij
i
d
j
k
ij
i
d
i
lasso 1,1 ridge F
2
group 2,1
lasso
1 1
ridge
1 1
2
group
1
T
2∑ ∑ ∑ ∑ ∑
λ = ∥ ∥ + ∥ ∥ + ∥ ∥ =
= | | + + ∥ ∥
= = = = =
(2)
where ei is an ith unit vector, which conforms to the
dimensionality of its context. The algorithm relies on single
penalty functions or their combinations by setting the proper
regularization coefficients Classo, Cridge, and Cgroup.
We investigated the influence of regularization coefficients,
the rank of low-rank matrix W, and the number of training
iterations on the predictive ability of RS in the case of antiviral
activity data. The ranges of the investigated hyperparameter
values are provided in Supporting Information Table S1.
2.2. Data Preparation. We used ViralChEMBL45 as the
source of information about compound−virus interactions to
Figure 1. Scheme of data preparation.
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create data sets for cross-validation and model training. The
ViralChEMBL data set contains 615 029 antiviral activity data
points extracted from ChEMBL v.20, standardized and
annotated by virus species according to ICTV taxonomy. We
prepared compound−virus interaction data based on the
workflow depicted in Figure 1 and described in the Supporting
Information. As a result of the data processing, the DB_main
data set for training and cross-validation comprised 247 994
compounds, 158 viral species, and 400 281 interaction values.
External validation was based on compound−virus inter-
action information from ChEMBL v.24 for the period 2017−
2019.53 Test sets were prepared for assessment of the interaction
prediction quality in two cases: for known compounds and
viruses (DB_ext_points) and for new compoundscompound-
wise CS prediction (DB_ext_CS). DB_ext_points consisted of
659 interactions between 447 compounds and 43 viral species,
while DB_ext_CS contained 10 730 interactions between
10 730 compounds and 55 viral species. The descriptive
statistics of the data sets are given in Table 1.
2.2.1. Compound Features. Two-dimensional descriptors of
chemical structures were calculated with Dragon 7.0.854 and
used as the features of the compounds. Descriptors were
calculated and selected with default options, except the
following set “on”: (1) exclude descriptors with constant and
near-constant values, (2) exclude descriptors with a standard
deviation (SD) of <0.0001, (3) exclude descriptors with all
missing values, and (4) round descriptor values. The features
with “NaN” values were dropped according to the SGIMC
requirements. The selected features were standardized with the
StandardScaler class of the sklearn.preprocessing module. The
resulting compound feature matrices DB_c.main, DB_c.ext_-
points, and DB_c.ext_CS were composed of 2016 feature
columns and different numbers of compound rows (Table 1).
For an additional cross-validation test, we reduced the
number of features to investigate their influence on the
predictivity. DB_c.50d, DB_c.25d, and DB_c.10d contained
reduced number of features, up to 50, 25, and 10%, respectively.
DB_c.8 contained only eight simplest features: AMW, average
molecular weight; nSK, number of non-hydrogen atoms; snBO,
number of non-hydrogen bonds; sRBN, number of rotatable
bonds; nDB, number of double bonds; sMLOGP, Moriguchi
octanol−water partition coefficient (logP); nHDon, number of
hydrogen bond donors (N and O); and nHAcc, number of H-
bond acceptors (N, O, F). DB_c.1 was the unit feature vector
with the sole feature equal to 1 for all compounds. Feature
selection for DB_c.50d, DB_c.25d, and DB_c.10d data sets was
performed in three random replicates to ensure the robustness of
selection.
2.2.2. Viral Species Features. We used viral species
(species_id) and genus (genus_id) information from
the ViralChEMBL data set according to the ICTV 2014
taxonomy.45,55 We exploited the genus assignment as the only
(pseudo)feature of the species and represented it as a binary
vector according to the following rule: if a species belonged to a
genus, then the bit corresponding to the genus_id was set to
1, otherwise to 0. The resulting viral featurematricesDB_v.main,
DB_v.ext_points, and DB_v.ext_CS contained 74 feature
columns. It was not expected that such features should contain
sufficient predictive information. The utilization of viral feature
matrices was mandatory in the SGIMC method, while the
models were designed with mostly compound feature-based
prediction in mind.
2.3. Prediction Scenarios. Three main challenges can be
addressed in the multitask prediction (Figure 2): prediction of
new interactions for compounds and viruses, data for which were
used for model building (Figure 2a), prediction of interaction
Table 1. Data Sets for Model Training, Cross-Validation, and
External Validation
interaction data sets DB_main DB_ext_points DB_ext_CS
number of
compounds
247 994 447 10 730
number of viral
species
158 43 56
number of
interactions
400 281 659 10 730
active/inactive class
ratio
9/1 3/1 4/1
minimum/average/
maximum number
of interactions with
viruses for each
compound
1/1.61/36 1/1.47/12 1/1/1
minimum/average/
maximum number
of interactions with
compounds for each
virus
1/2533.42/85 823 1/15.33/155 1/195.09/2621
sparsity 1.02% 3.43% 1.82%
virus feature sets DB_v.main DB_v.ext_points DB_v.ext_CS
number of species features 74 74 74
compound
feature sets
DB_c.main/DB_c.50d/
DB_c.25d/DB_c.10d/
DB_c.8/DB_c.1 DB_c.ext_points DB_c.ext_CS
number of
compound
features
2016/1008/504/202/8/1 2016 2016
Figure 2. Addressed challenges: (a) prediction of point compound−virus interactions, (b) compoundwise CS prediction, and (c) specieswise CS
prediction. Matrix of interactions, green; matrix of species features, pink; matrix of compound features, yellow; and unknown compound−virus
interactions, white.
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profiles for compounds that were not used for model building
(compoundwise CS prediction) (Figure 2b), and prediction of
interactions for viral species that were not used for model
building (specieswise CS prediction) (Figure 2c). We assessed
the performance of the methods in all three scenarios, where
possible.
CF algorithms process only the interactionmatrix and thereby
cannot perform CS predictions. Thus, Surprise CF algorithms
were used to address only the prediction of new interactions
between compounds and viruses utilized for model building
(Figure 2a). Hyperparameters for the best models were selected
by grid search (Supporting Information Table S1) and 10-fold
cross-validation in the model_selection module. Models were
based on the DB_main data set and external validation was
performed on the DB_ext_points data set.
The SGIMC CBF algorithm was applied for solving all three
challenges (Figure 2). Models were trained on the interaction
matrix DB_main with side feature matrices DB_c.main and
DB_v.main. External validation was performed using the
interaction matrix DB_ext_points and the feature matrices
DB_c.ext_points and DB_v.ext_points in the case of interaction
prediction for known compounds and species and using
matrices DB_ext_CS, DB_c.ext_CS, and DB_v.ext_CS in the
case of compoundwise CS prediction. Model selection was
performed based on a grid search of hyperparameters
(Supporting Information Table S1) and cross-validation. We
used sklearn.model_selection v.0.21.3 classes KFold for 10-fold
cross-validation in the compoundwise CS scenario and
Stratif iedKFold for stratified 10-fold cross-validation of
prediction of new interactions of known compounds and viruses
due to substantial data set imbalance.
Models for solving specieswise CS problems were built
without cross-validation using DB_main, DB_c.main, and
DB_v.main data sets and hyperparameters of the best model
for prediction of new interactions between known compounds
and viral species. Model building and evaluation were performed
by excluding the activity profiles of each species one by one from
the model building and applying them as external test sets. Due
to a small number of interaction values for the majority of
species, the assessment of their prediction power could not be
accurate.
2.3.1. Influence of the Number of Features. We carried out
an additional test to investigate the influence of the number of
features on the predictive power of the SGIMC algorithm. The
model for the DB_mainmatrix was built. Feature matrices were
represented byDB_v.main andDB_c.main subsets with different
numbers of features, three generated by random samplings:
DB_c.50d, DB_c.25d, and DB_c.10d, and two with fixed
features: DB_c.8 and DB_c.1. Assessment of prediction on
reduced matrices was based on the stratified 10-fold cross-
validation with hyperparameters from the best model for
prediction of interaction for known compounds and viruses
based on the original DB_c.main data set.
2.4. Evaluation and Metrics. Models were built based on
the DB_main set and validated via cross-validation and external
test sets (DB_ext_CS and DB_ext_points).56,57 To avoid
possible errors caused by the substantial imbalance of the data
set with regard to activity classes, we used stratified 10-fold
cross-validation keeping the constant proportion of active and
inactive class assignments (90 and 10%, respectively) in the
training and test sets.58 We used grid search to optimize the
hyperparameters of our algorithms. Varied hyperparameters and
their values are shown in Supporting Information Table S1.
We used the receiver operating characteristic area under the
curve (ROC AUC) score and two metrics based on it to assess
prediction quality. The ROC AUC score was calculated using
the roc_auc_score class of sklearn.metrics for all predicted
values.59 The mean and median of n-fold-averaged ROC AUC
for a set of viral species60 were also calculated
l
m
oo
n
oo
|
}
oo
~
ooN
t t T
mean/median ROCAUC
mean/median
1
ROC AUC ( ) 1, ...,
n
N
n
1
∑= | =
=
(3)
where ROC AUCn(t) is the ROC AUC score calculated for viral
species t for the test fold n,N = 10 in the case of cross-validation
and N = 1 in the case of external validation. Standard deviation
(SD) was calculated by numpy.std class (numpy v. 1.17.2).
We used the ROC AUC score to assess the prediction quality
for all of the interaction values in the test set. The mean and
median ROC AUC scores were used to demonstrate the
difference in prediction quality for the separate viral species. For
the comparison of models, we used median ROC AUC as the
main measure not skewed by extremely large or small values, so
it would better describe the real prediction quality. Also, SD was
defined as a deviation for predictions for different viral species in
the mean ROC AUC calculation and as a deviation in ROC
AUC values for different cross-validation runs. The quality of
specieswise CS prediction was assessed by the ROC AUC score
for each species separately. ROC AUC, mean and median ROC
AUC scores for the 10 best models for every algorithm are
collected in Supporting Information Tables S2−S9. A code
snippet for the metrics calculation is available as Supporting
Information File SI2.
The robustness of the models was assessed by y-scram-
bling.56,61 The median ROC AUC scores for normal models
were compared with the median ROC AUC scores of the ones
based on y-scrambled data sets. We used 1− (n/m) as a measure
of robustness,62,63 where m and n are the numbers of “normal”
and scrambledmodels with ROCAUC>0.6, respectively. The y-
scrambling was performed for the 10 best models in each
scenario according to the median ROC AUC score and was
applied for both cross-validation and external validation
(Supporting Information Tables S2−S9).
To assess the applicability of constructed models, we
compared training and test data sets based on the similarity
distance between their compounds. The distance was evaluated
between DB_c.main and DB_c.ext_points, between DB_c.main
and DB_c.ext_CS, and as an average of distances between
training and test sets in every fold in the case of cross-validation
(DB_c.main). The distance between each pair of compounds in
the training and test data sets was computed based on their
feature values. The cosine distance was calculated with the
spatial.distance.cdist class of the scipy package. The similarity
between the training and test sets was assessed based on the
distribution of distances between every ith compound in a test
set and all of the compounds in the training set (DISTi),
calculated according to the equation
n
N
DIST simi
j
T
j
i
ij
1
∑=
= (4)
where nj is the number of known interactions of the ith
compound of the test set and the jth compound of the training
set with the same viral species,Ni is the overall number of known
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interactions for the ith compound, and simij is the cosine
distance between the ith compound of the test set and the jth
compound of the training set containing T compounds.
3. RESULTS AND DISCUSSION
The efficiency of antiviral activity class prediction with CF and
CBF techniques was assessed and compared for small molecules
from ViralChEMBL and ChEMBL 24. We represented
compound−virus interactions as two classes, active and inactive,
and encoded them in the interaction matrix as 1 and 0,
respectively. In the case of a lack of experimental measurements,
the corresponding value was kept empty. To understand the
performance and robustness of the RS approaches, we
investigated four scenarios:
• prediction of point interactions for known compounds
and viruses,
• compoundwise CS prediction (prediction of interaction
profiles for new compounds),
• specieswise CS prediction (prediction of interaction
profiles for new viruses), and
• prediction of compound−virus interactions with a
reduced number of compound features.
In all of the scenarios, the ROC AUC scores for the best models
were much higher than the corresponding mean and median
ROC AUC (Supporting Information Tables S2−S9). Thus, the
ROC AUC scores could be used only to illustrate how precise
the prediction was for all of the interaction values in the test set.
It was calculated based on all predicted values and did not take
into account the specifics of each viral species. At the same time,
the mean/median ROC AUC was the average/median of ROC
AUC values separately calculated for each viral species. A
moderate mean/median ROC AUC value and a high SD of the
mean ROC AUC indicated satisfactory prediction for the whole
data set along with a substantial difference in prediction power
for different viral species: the activity class prediction based on
the same model for some viral species was perfect, while for the
others it was unsatisfactory.
We performed 10-fold cross-validation and optimized hyper-
parameters of models by grid search. To prove the lack of impact
of data set imbalance on the prediction results, the y-scrambling
test was performed for the 10 best models under each scenario in
both cross-validation and external validation settings (Support-
ing Information Tables S2−S9). Upon y-randomization, the
quality of models decreased, providing compelling evidence of
the relevance of our prediction model.
We examined the opportunity of using the Balanced Accuracy
and the Precision-Recall AUC as model quality metrics.59 Their
use led to overestimation of prediction results:59 for the best
models, their values were equal to 0.98−0.99. Thus, we did not
use them for the model assessment. We also did not assess the
accuracy of our models because it is easy to get high accuracy
even for a poor model for an imbalanced data set.64 We did not
use specificity, sensitivity/recall, precision, median balanced
accuracy, and similar metrics that are suitable for imbalanced
data because these metrics require an active/inactive threshold,
which is not applicable for a data set based on several targets.
We also evaluated the similarity of data sets by comparing the
distance from each compound in the test set to all of the
compounds in the training sets. The results are presented in
Supporting Information Figure S1 and Table S10. External test
sets were found to consist of compounds that are more distant
from the training set compounds compared with the compounds
in the training and test sets during cross-validation.
3.1. Predictionof Point Interactions. 3.1.1. Collaborative
Filtering. We explored three collaborative filtering techniques:
k-nearest neighbors, coclustering, and matrix factorization. The
performance of the best models is given in Table 2 and is
illustrated in Figure 3.
It should be noted that the cross-validation prediction results
in Surprise suffer from the CS problem. Due to a high data set
sparsity, more than 60% of the compounds possess only one
interaction (it is about 40% of compound−species interactions
in the DB_main). Predicted values for these compound−virus
pairs during cross-validation will be equal to the mean of all
interactions from their viral species profile.
Table 2. Predictivity of Surprise Models
cross-validation external validation
Surprise methods ROCAUC± SD
mean ROC AUC ±
SD
median ROC
AUC
ROC
AUC
mean ROC AUC ±
SD
median ROC
AUC
knns.KNNBasic msd (virus-based) 0.808 ± 0.004 0.8 ± 0.3 0.86 0.603 0.7 ± 0.3 0.72
knns.KNNBasic msd (compound-based) 0.888 ± 0.004 0.8 ± 0.3 0.83 0.888 0.8 ± 0.3 0.83
knns.KNNBasic cosine (virus-based) 0.806 ± 0.005 0.8 ± 0.3 0.86 0.606 0.7 ± 0.3 0.75
knns.KNNBasic cosine (compound-based) 0.872 ± 0.004 0.7 ± 0.3 0.79 0.872 0.7 ± 0.3 0.75
co_clustering.CoClustering 0.863 ± 0.01 0.7 ± 0.3 0.81 0.702 0.7 ± 0.3 0.76
matrix_factorization.SVD 0.939 ± 0.003 0.8 ± 0.3 0.88 0.764 0.7 ± 0.3 0.78
matrix_factorization.NMF 0.939 ± 0.003 0.8 ± 0.3 0.88 0.709 0.7 ± 0.3 0.68
Figure 3. Violin plot of ROC AUC values for viral species in cross-validation (blue) and external validation (red). Dotted lines inside the violins
represent the quartiles of the distribution.
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KNNBasic methods are directly derived from the k-nearest-
neighbors approach and follow the basic paradigm of chemo-
informatics: similar compounds possess similar properties. In
our case, this statement can also be extended as follows: similar
compounds interact with similar viruses and similar viruses are
inhibited by similar compounds. The similarity is calculated for
the interaction profiles of compounds or viruses. The perform-
ance of models varies depending on the similarity metric as well
as the direction of similarity calculation: virus- or compound-
based similarity. Compound-based models demonstrate better
predictive power (Table 2). However, the similarity calculation
is both the key factor and the bottleneck of this algorithm. Upon
an increase of the number of interaction profiles N, the
predictive power of the model increased, probably due to the
increase of the information capacity of the similarity matrix, but
at the same time, space and time complexity is O(N2). It makes
the applicability of similarity-based CFmethods limited for large
data sets. For example, the DB_main data set required at most
1.5 GB RAM and a dozen seconds for the calculation of an msd
or cosine similarity matrix for 158 viral species. The same data
set required at least 1700 GB RAM and 2 h or 2500 GB and 6 h
for an msd or cosine calculation of 250K compounds,
respectively.
Methods based on coclustering and matrix factorization do
not rely on profile similarity; therefore, they do not need large
RAM resources (no more than 1.5 GB of RAM) and take several
minutes under the same computational conditions as those for
KNNBasicmethods. In the coclustering, rows and columns of an
interaction matrix are simultaneously grouped to compare the
profiles and complete the missing values. The best coclustering
Figure 4.Guided grid search ofClasso,Cridge, andCgroup coefficients for interaction prediction for known compounds and viral species based on (a) ROC
AUC, (b) mean ROC AUC, and (c) median ROC AUC. Rank = 10, number of iterations = 70.
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model shows a cross-validation median ROC AUC of 0.81,
which is between the cosine virus-based kNN (0.79) and
compound-based kNN (0.86). Both compound- and virus-
based msd also perform better than coclustering in the cross-
validation (median ROC AUCs of 0.83 and 0.86). For the test
set, the median ROC AUC is almost the same for coclustering
and kNN methods (around 0.75), except for compound-based
msd (0.83). Thus, coclustering may be used in place of kNN if
the computational resources are limited.
The matrix factorization approach solves the problem of
matrix completion by finding latent features that determine the
internal relationship in data (in our case, between compounds
and viruses). Models based on this approach showed the best
performance in the 10-fold cross-validation protocol: median
ROC AUC = 0.88 in both cases. On the test set, the NMF
models demonstrated the worst performance (median ROC
AUC = 0.68), while the prediction power of the SVD models
(median ROC AUC = 0.78) is second only to the msd
compound-based kNN model (median ROC AUC = 0.83).
3.1.2. CBF Prediction of Point Interactions with SGIMC.The
problem of matrix completion is considered as an optimization
procedure using the features of compounds and viruses. The
SGIMC algorithm shares the idea of the IMC approach of matrix
completion by combining feature vectors, associated with row
and column entities of the interaction matrix, with a low-rank
matrix. Three matrices are required to train an SGIMCmodel: a
partially filled interaction matrix and full feature matrices for
compounds and viruses. Our compound feature matrix
DB_c.main was filled with Dragon descriptors, whereas the
virus feature matrix DB_v.main included only genus assign-
ments. By design, SGIMC has an option for feature selection,
which is implemented through a sparsity-inducing penalty and
its regularization coefficient Cgroup. Also, coefficients Cridge and
Classo, representing the squared Frobenius norm and the matrix
L1-norm penalties, respectively, are involved in regularization.
These regularization coefficients were varied along with the rank
of the internal low-rank matrix W and the number of training
iterations to choose the best SGIMC model.
For our best model (median ROC AUC = 0.84), we have the
following hyperparameters: rank = 10, number of iterations = 70,
Classo = 0.0, Cridge = 120.0, and Cgroup = 0.0. An increase of Classo
and Cgroup leads to a notable decrease of performance, while an
increase of Cridge leads to its slight increase, followed by a slow
descent (Figure 4) after the optimal Cridge value of about 120.
3.2. Cold-Start Prediction with CBF. The cold-start
problem is a possible lack of performance of a recommender
system applied to a new compound or virus, for which there is no
experimental data. In particular, the problem is critical for
collaborative filtering methods, based on the interaction matrix
only. To tackle this issue, CBF approaches (e.g., SGIMC), based
on available side-channel information (features of compounds/
viruses), may be used to obtain reliable predictions in the cold-
start mode.
We established the hyperparameters for the best SGIMC
model for the compoundwise CS prediction based on a cross-
validation grid search. The compoundwise CS performance
appeared not to differ substantially from prediction for known
compounds and viruses in the quality of interaction prediction
(Figure 5). For example, the models with one of the highest
predictive powers (median ROC AUCs of 0.82 and 0.86,
respectively) were built on the same hyperparameter set: rank =
10, number of iterations = 70, Classo = 0.0, Cridge = 120.0, and
Cgroup = 0.0. Test set efficiency of the model based on these
hyperparameter values was assessed by median ROC AUC,
which was equal to 0.71 and 0.69 for compoundwise CS
prediction and point interaction prediction for known
compounds and viruses, respectively (Figure 5a,b). A substantial
decrease in predictive quality for external test sets is a result of
differences between their compounds and compounds in the
training set.
SGIMC models for specieswise CS prediction based on the
interaction matrix DB_main and feature matrices DB_c.main
Figure 5. Violin plots of ROC AUC values for viral species: (a) prediction of point compound−virus interactions, (b) compoundwise CS prediction,
and (c) specieswise CS prediction. The prediction was assessed in cross-validation (light blue and coral) and external validation (dark blue, red, and
green). Lines depict the dependence of median ROC AUC scores on the number of iterations. Dotted lines inside the violins represent the quartiles of
the distribution. Rank = 10, Classo = 0.0, Cgroup = 0.0, and Cridge = 120.0.
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and DB_v.main appeared to be inferior to the models for
compoundwise CS prediction (Figure 5b,c) (Supporting
Information Tables S3 and S4). In specieswise CS prediction,
the median value of ROC AUC for all viral species is 0.65 at 70
iterations, while it is 0.75 in the case of compoundwise CS
prediction on the external test set (rank = 10, Classo = 0.0, Cridge =
120.0, Cgroup = 0.0). Moreover, the distribution of median ROC
AUC values for new compounds (Figure 5b) is more shifted
toward the 1 than the distribution of ROC AUC values for new
species (Figure 5b). For example, the top quartile is more than
0.9 for compoundwise CS prediction and more than 0.8 for
specieswise CS prediction, while the bottom quartile is close to
0.5 in both cases.
The decrease of the predictive power in the specieswise CS
was apparently caused by the insufficient virus features,
represented by the genus assignment only. To prove this
hypothesis, we modeled the situation with absolutely unin-
formative features by replacing DB_c.main and DB_v.main
matrices with unit vectors (Figure 6). It is clear that the models
based on the original feature matrices possess the best predictive
quality (Figure 6, red). In the case of unit vector for species
(Figure 6, blue), models were based on sufficient information
from compound features and were still able to predict
interaction values, though with lower prediction quality. In the
case of unit vector for compounds (Figure 6, green), interaction
prediction was not meaningful, indicating that the original
species features are not sufficient. We hope that the proper
introduction of virus features will improve the results for all
scenarios.
3.3. Influence of the Number of Features. The
compound feature information in the DB_c.main matrix is
redundant, so we supposed that the features could be randomly
removed without a significant deterioration in prediction
quality. To assess this hypothesis, we carried out a series of
experiments for known compounds and viruses by replacement
of the DB_c.main matrix with truncated feature matrices
DB_c.50d, DB_c.25d, DB_c.10d, DB_c.8, and DB_c.1.
This experiment showed that compound feature information
in DB_c.main is excessive for the SGIMC models (Figure 7).
Reducing the feature number up to 50, 25, and 10%
continuously, but slightly, reduced the prediction quality of
the models. For the models built on the DB_c.main, DB_c.50d,
DB_c.25d, and DB_c.10d sets, the median ROC AUC scores
were 0.81, 0.78, 0.74, and 0.72, respectively (rank = 10, number
of iterations = 60, Classo = 0.0, Cridge = 120.0, Cgroup = 0.0). With
the same hyperparameters, the models based on the eight
simplest features demonstrated a critical decrease of the
prediction quality, with the median ROC AUC = 0.67. The
models based on unit vectors were not predictive at all.
SGIMC allows one to select features using the Cgroup penalty
coefficient to filter out the noninformative ones. The selection of
the most significant features is performed by the increase of the
Cgroup coefficient: with its increase, the number of selected
features is decreased. In the SGIMC authors’ benchmarks, the
method was able to select about 6000 features from the set of
355 709.52 However, in our experiment, the increase ofCgroup led
to a decrease of the mean/median ROC AUC values and,
thereby, the predictive quality of a model. The extent of the
decrease depended on the other hyperparameters (Figure 8).
It is clear from the comparison of Figures 7 and 8 that the
models based on the same number of selected compound
features possess different predictive powers depending on
whether the features were selected randomly (Figure 7) or
using the Cgroup coefficient (Figure 8). For example, in cross-
validation for point interaction prediction with 50% of the
compound features, ROC AUC scores were 0.79 for the models
with random selection and 0.68 for the models with Cgroup
selection (number of iterations = 70, rank = 10,Classo = 0.0, Cridge
= 120.0). It was a result of an application of the Cgroup coefficient
for both compound and species feature selections, i.e., using
Cgroup led to zeroing of both compound and species features
simultaneously. The strategy of a simultaneous feature selection
is smart in the case of a huge amount of noisy features, which is
not the case in our task, characterized by the insufficiency of
Figure 6. Dependence of the median ROC AUC score for point
interaction prediction on number of iterations through cross-validation
with original feature matrices (red), unit vector for species (blue), and
unit vector for compounds (green) (rank = 10, Classo = 0.0, Cgroup = 0.0,
and Cridge = 120.). Error bars represent the SD.
Figure 7.Dependence of mean ROCAUC (a) andmedian ROCAUC (b) for models with a different number of compound features on the number of
iterations. Rank = 10, Classo = 0.0, Cgroup = 0.0, and Cridge = 120.0. Compound feature matrices: DB_c.main (red ★), DB_c.50d (blue ■), DB_c.25d
(magenta◆), DB_c.10d (green ×), DB_c.8 (orange •), and DB_c.1 (light blue ▲). Error bars represent the SD.
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species features. It led to a critical loss of feature information and
deterioration of model quality. Separate determination of
regularization coefficients for both compound and species
feature matrices should be a solution to this problem.
4. CONCLUSIONS
Multitask prediction algorithms have been gaining ground
rapidly with the appearance of databases storing multitarget
data. The recommender system (RS) as an approach of
multitask prediction may be a powerful tool for compound−
target interaction prediction. These methods allow one to
predict the activity class for all combinations of compounds and
targets in a data set and select the best of them for further
experimental investigations. However, the current experience in
this domain is limited and far from complete.
Our experiments demonstrated that RS algorithms based on
collaborative and content-based filtering to a sparse matrix of
antiviral activity data can achieve sustainable performance for
the antiviral activity class prediction. We revealed that both
approaches showed a very high predictive ability in cross-
validation and external validation as measured by ROC AUC
and mean/median ROC AUC.
Collaborative filtering (CF) methods demonstrate high
performance but they possess several crucial limitations. The
models based on the calculation of compound profile similarity
demonstrate the best predictive ability among the investigated
CF methods but the application of these methods is challenging
due to the requirement of a huge amount of RAM for the
similarity calculation and storage. Improvement of the algorithm
by reducing the required RAM during model building would
allow the wider use of these methods for data sets with
thousands of compounds. The matrix factorization methods
lead to models with moderate predictive ability. Their
preference over other CF methods is determined by the
simplicity of their application. The main disadvantage of all CF
methods is a limited applicability domain: we can make a
prediction only for compounds or viruses whose interaction
profiles were used during model creation.
The application of content-based filtering (CBF) algorithms
is preferable because of the possibility of using feature
information for compounds and viruses. Using compounds’
features, CBF makes the cold-start prediction possible. The
main disadvantage of the approach is the requirement of
generation and processing of additional feature information,
which can be a challenging task in the case of viruses, and may
require a lot of computational resources. The SGIMC method
allows one to reduce the number of used features to several
thousand, which was not possible in our case with only 2016
features. Without feature selection, the SGIMC algorithm was
virtually reduced to the IMC. Using this algorithm, we
demonstrated that the prediction of antiviral activity for both
new and known compounds against known viruses can be
performed with rather high accuracy, while prediction of the
antiviral activity of known compounds against new viruses was
less accurate due to the insufficient characterization of the
viruses in our data set. We believe that the development of
appropriate virus features could solve the problem; however, it
may be a tricky issue by itself.
This research revealed promising applicability and effective-
ness of the RS approaches in drug discovery. We hope that
further progress in this field can be achieved with hybrid RS
approaches that can make the best of CF and CBF models.
■ APPENDIX: TERMINOLOGICAL ISSUES IN THE RS
FIELD
RS approaches have evolved rapidly in the field of e-commerce
and have found extensive application in other fields. Although
their application was common, there was a tendency to study
these approaches in different communities under different
names. Therefore, despite the fact that the term “recommender
systems” has begun to appear in drug discovery research only in
the last few years,65 methods based on them began to be
exploited around a decade ago.36,66−68 The clearest example is
the proteochemometric approach8,9 and “read across” meth-
ods.11 Also, there is a terminological confusion even within the
same community. For example, the matrix of multitarget
multicompound interaction data with columns corresponding
to the compounds and rows corresponding to the targets may be
called “interaction matrix”,69,70 “interaction space”,9 or “target
matrix”.71
This terminological inconsistency led to the lack of RS terms
in the publications related to drug discovery. Analysis of the
publishing activity by related queries (“recommender systems”,
“recommendation systems”, “collaborative filtering”, “content-
based filtering”, and “drug”) in the title, abstract, and keywords
in Scopus and Dimensions72,73 showed that interest in the
application of RS for drug discovery and design has appeared
since 2012. Nevertheless, algorithms, on which RS are based,
have been applied to this field for decades and have generated
greater interest.
To avoid confusion in terminology, in this article, multitarget
data are represented and defined as interaction matrix M.
Commonly,13 it may be represented by triplets (xi, yj, mij) of
instances x∈X, targets y∈Y, and scores of their relationshipm∈
M. In drug discovery, triplets are represented by compounds,
their biological targets, and their interactions, defined as the
Figure 8. Influence of theCgroup regularization coefficient in cross-validation for point interaction prediction on themean/median ROCAUC at 70 (a)
and 10 (b) iterations. Continuous and dashed red lines indicate the mean and median ROC AUC, and continuous and dashed blue lines indicate the
mean andmedian number of zeroed features. Shaded areas represent the corresponding standard deviations. The black dash-dotted line shows median
ROC AUC with 50% of compound features. Classo = 0.0, Cridge = 120.0, and rank = 10.
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activity of the compounds against these targets. The vector of
interactions for each target or compound forms an interaction
profile. Interactions may be represented by nominal, ordinal, or
real values. In the drug discovery context, they may correspond
to activity values (e.g., IC50, Ki) or activity classes (e.g., boolean:
0, inactive; 1, active; and multiclass: 3, high activity; 2, moderate
activity; 1, weak activity; 0, inactive). Scores of compound−
target interaction generated by an RS are referred to as
recommended values.
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prediction: a unifying view on problems andmethods.DataMin. Knowl.
Discovery 2019, 33, 293−324.
(14) Bennett, J.; Elkan, C.; Liu, B.; Smyth, P.; Tikk, D. KDD Cup and
Workshop 2007. SIGKDD Explor. Newsl. 2007, 9, 51−52.
(15) Amatriain, X.; Basilico, J. Recommender Systems Handbook; Ricci,
F.; Rokach, L.; Shapira, B., Eds.; Springer US: Boston, MA, 2015; pp
385−419.
(16) Thorat, P. B.; Goudar, R. M.; Barve, S. Survey on Collaborative
Filtering, Content-based Filtering and Hybrid Recommendation
System. Int. J. Comput. Appl. 2015, 110, 31−36.
(17) Aggarwal, C. C. Recommender Systems: The Textbook, 1st ed.;
Springer Publishing Company, Inc., 2016.
(18) Sanghavi, B.; Rathod, R.; Mistry, D. M. Recommender Systems-
Comparison of Content-based Filtering andCollaborative Filtering. Int.
J. Curr. Eng. Technol. 2014, 4, 3131−3133.
(19) Aggarwal, P.; Tomar, V.; Kathuria, A. Comparing Content Based
and Collaborative Filtering in Recommender Systems. Int. J. New
Technol. Res. 2017, 3, 3.
(20) Ariff, N. M.; Bakar, M. A. A.; Rahim, N. F. InComparison Between
Content-based and Collaborative Filtering Recommendation System for
Movie Suggestions, AIP Conference Proceedings; AIP Publishing LLC:
Kuala Lumpur, Malaysia, 2018; p 020057.
(21) Su, X.; Khoshgoftaar, T. M. A Survey of Collaborative Filtering
Techniques. Adv. Artif. Intell. 2009, 2009, 1−19.
(22) Nilashi, M.; Bagherifard, K.; Ibrahim, O.; Alizadeh, H.; Nojeem,
L. A.; Roozegar, N. Collaborative Filtering Recommender Systems. Res.
J. Appl. Sci., Eng. Technol. 2013, 5, 4168−4182.
(23) Sharma, M.; Mann, S. A Survey of Recommender Systems:
Approaches and Limitations. Int. J. Innov. Sci. Eng. Technol. 2013, 1−9.
(24) Cacheda, F.; Carneiro, V.; Fernańdez, D.; Formoso, V.
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